A Phase 2 interventional study of Pemigatinib in Solid Tumor Malignancy, sponsored by Incyte Corporation. Terminated at 90 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-04.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Acrocephalosyndactylia with a site in United States — none open to participants now, 1 under way, none of them phase 3. Acrocephalosyndactylia · United States.
Among the 16 studies in Acrocephalosyndactylia with a site in United States, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2019, is one of 8 in phase 2, and was the 10th registered.
33 studies on the registry are indexed under Acrocephalosyndactylia; 6 are open to participants now.
Browse Acrocephalosyndactylia studies →None of the 16 studies in Acrocephalosyndactylia with a site in United States is open now. The open studies under Acrocephalosyndactylia, anywhere →
Of the 5 Acrocephalosyndactylia studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10
First in 2005; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 51 across 25 interventional studies indexed under Acrocephalosyndactylia.
Median enrollment 44 across the 14 interventional studies, 1,862 across the 2 observational. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 16 have an industry lead sponsor. The 8 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Incyte Corporation has 7 studies filed under Acrocephalosyndactylia — fewer than ten, so there is no comparison to draw.
1 of the studies in Acrocephalosyndactylia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06160752Tyra Biosciences, IncSafety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Acrocephalosyndactylia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort A (Solid tumor malignancies with FGFR1-3 in frame fusions; any FGFR2 rearrangement; FGFR1/3 rearrangement with known partner\*). Cohort B (Solid tumor malignancies with known or likely activating mutations (excluding kinase domain) in FGFR1-3) Cohort C (Solid tumor malignancies with FGFR1-3 known activating mutations in kinase domain; FGFR1-3 putatively activating mutations; other FGFR1/3 rearrangements\* (not eligible for Cohort A)). \*Only FGFR fusions or rearrangements with an intact kinase domain are eligible
Drug: Pemigatinib
Pemigatinib administered orally once daily (QD).
Also known as: INCB054828
Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements
Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1): CR: disappearance of all target/non-target lesions; no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters; no new lesions; no progression of non-target lesions. Per Response Assessment in Neuro-Oncology (RANO; for participants with primary brain tumors): CR: disappearance of all enhancing lesions; stable/improved non-enhancing lesions; stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable enhancing lesions; no progression of non-measurable disease; stable/improved non-enhancing lesions; stable/improved clinically. Cohort determination was based on FGFR status from a central genomics laboratory. Response data were from an independent centralized radiological review committee per RECIST v1.1 and RANO, and response was confirmed.
Time frame: up to 483 days
ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations
Per RECIST v1.1: CR: disappearance of all target/non-target lesions; no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters; no new lesions; no progression of non-target lesions. Per RANO (for participants with primary brain tumors): CR: disappearance of all enhancing lesions; stable/improved non-enhancing lesions; stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable enhancing lesions; no progression of non-measurable disease; stable/improved non-enhancing lesions; stable/improved clinically. Cohort determination was based on FGFR status from a central genomics laboratory. Response data were from an independent centralized radiological review committee per RECIST v1.1 and RANO, and response was confirmed.
Time frame: up to 449 days
Progression-free Survival (PFS) in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations
PFS was defined as the time from the first dose until progressive disease (according to RECIST v1.1 or RANO for participants with primary brain tumors and assessed by an independent centralized radiological review committee) or death (whichever occurred first).
Time frame: up to 532 days
Duration of Response (DOR), Defined as the First CR or PR Assessment Until Progressive Disease (PD) or Death, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations
Assessment was by an independent centralized radiological review committee; response was confirmed. Per RECIST v1.1: CR: disappearance of all target (TLs)/non-target lesions (NTLs); no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of TLs, taking as a reference the baseline sum diameters; no new lesions; no progression of NTLs. PD: progression of a TL/NTL or presence of new lesion. Per RANO (participants with primary brain tumors): CR: disappearance of all enhancing lesions (ELs); stable/improved non-enhancing lesions (NELs); stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable ELs; no progression of non-measurable disease; stable/improved NELs; stable/improved clinically. PD: \>25% increase in sum of perpendicular diameters of all measurable ELs; significant increase of NELs; new lesions; clear clinical deterioration; failure to return for evaluation due to death/deteriorating condition.
Time frame: up to 24.90 months
Overall Survival in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations
Overall survival was defined as the time from the first dose of study drug to death of any cause.
Time frame: up to 532 days
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-related Adverse Event (AE)
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. TEAEs were defined as AEs reported for the first time or the worsening of pre-existing events after the first dose of study treatment. Treatment-related AEs were defined as TEAEs judged as related by the investigator or with a missing causality.
Time frame: up to 651 days
| Milestone | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other |
|---|---|---|---|---|
| Started | 49 | 32 | 26 | 4 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 49 | 32 | 26 | 4 |
| Withdrew: Death | 18 | 17 | 12 | 4 |
| Withdrew: Lost to follow-up | 1 | 2 | 3 | 0 |
| Withdrew: Study terminated by sponsor | 25 | 11 | 6 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 3 | 0 |
| Withdrew: Disease progression | 1 | 2 | 1 | 0 |
| Withdrew: Never returned to hospital | 0 | 0 | 1 | 0 |
Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1): CR: disappearance of all target/non-target lesions; no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters; no new lesions; no progression of non-target lesions. Per Response Assessment in Neuro-Oncology (RANO; for participants with primary brain tumors): CR: disappearance of all enhancing lesions; stable/improved non-enhancing lesions; stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable enhancing lesions; no progression of non-measurable disease; stable/improved non-enhancing lesions; stable/improved clinically. Cohort determination was based on FGFR status from a central genomics laboratory. Response data were from an independent centralized radiological review committee per RECIST v1.1 and RANO, and response was confirmed.
| percentage of participants | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other |
|---|---|---|---|---|
| Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements | 26.5 (14.95 to 41.08) | — | — | — |
Per RECIST v1.1: CR: disappearance of all target/non-target lesions; no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters; no new lesions; no progression of non-target lesions. Per RANO (for participants with primary brain tumors): CR: disappearance of all enhancing lesions; stable/improved non-enhancing lesions; stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable enhancing lesions; no progression of non-measurable disease; stable/improved non-enhancing lesions; stable/improved clinically. Cohort determination was based on FGFR status from a central genomics laboratory. Response data were from an independent centralized radiological review committee per RECIST v1.1 and RANO, and response was confirmed.
| percentage of participants | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other |
|---|---|---|---|---|
| ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations | — | 9.4 (1.98 to 25.02) | — | — |
PFS was defined as the time from the first dose until progressive disease (according to RECIST v1.1 or RANO for participants with primary brain tumors and assessed by an independent centralized radiological review committee) or death (whichever occurred first).
| months | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other |
|---|---|---|---|---|
| Progression-free Survival (PFS) in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations | 4.53 (3.58 to 6.28) | 3.68 (2.07 to 4.47) | — | — |
Assessment was by an independent centralized radiological review committee; response was confirmed. Per RECIST v1.1: CR: disappearance of all target (TLs)/non-target lesions (NTLs); no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of TLs, taking as a reference the baseline sum diameters; no new lesions; no progression of NTLs. PD: progression of a TL/NTL or presence of new lesion. Per RANO (participants with primary brain tumors): CR: disappearance of all enhancing lesions (ELs); stable/improved non-enhancing lesions (NELs); stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable ELs; no progression of non-measurable disease; stable/improved NELs; stable/improved clinically. PD: \>25% increase in sum of perpendicular diameters of all measurable ELs; significant increase of NELs; new lesions; clear clinical deterioration; failure to return for evaluation due to death/deteriorating condition.
| months | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other |
|---|---|---|---|---|
| Duration of Response (DOR), Defined as the First CR or PR Assessment Until Progressive Disease (PD) or Death, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations | 7.79 (4.17 to NA) | 6.93 (4.01 to NA) | — | — |
Overall survival was defined as the time from the first dose of study drug to death of any cause.
| months | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other |
|---|---|---|---|---|
| Overall Survival in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations | 17.48 (7.79 to NA) | 11.37 (6.57 to NA) | — | — |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. TEAEs were defined as AEs reported for the first time or the worsening of pre-existing events after the first dose of study treatment. Treatment-related AEs were defined as TEAEs judged as related by the investigator or with a missing causality.
| Participants | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other |
|---|---|---|---|---|
| TEAEs | 49 | 32 | 26 | 4 |
| Treatment-related AEs | 46 | 32 | 26 | 4 |
Collected over up to 651 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | 18/49 (36.7%) | 21/49 (42.9%) | 49/49 (100%) |
| Cohort B: Known or Likely Activating FGFR1-3 Mutations | 17/32 (53.1%) | 7/32 (21.9%) | 32/32 (100%) |
| Cohort C: Other FGFR Mutations or Arrangements | 13/26 (50%) | 10/26 (38.5%) | 26/26 (100%) |
| Other | 4/4 (100%) | 2/4 (50%) | 4/4 (100%) |
| Total | 52/111 (46.8%) | 40/111 (36%) | 111/111 (100%) |
| Event | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other | Total |
|---|---|---|---|---|---|
| CholangitisHepatobiliary disorders | 0/49 | 0/32 | 0/26 | 1/4 | 1/111 |
| DehydrationMetabolism and nutrition disorders | 0/49 | 0/32 | 0/26 | 1/4 | 1/111 |
| LymphopeniaBlood and lymphatic system disorders | 0/49 | 0/32 | 0/26 | 1/4 | 1/111 |
| General physical health deteriorationGeneral disorders | 0/49 | 1/32 | 2/26 | 0/4 | 3/111 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/49 | 0/32 | 2/26 | 0/4 | 2/111 |
| VomitingGastrointestinal disorders | 0/49 | 0/32 | 2/26 | 0/4 | 2/111 |
| Abdominal painGastrointestinal disorders | 3/49 | 0/32 | 0/26 | 0/4 | 3/111 |
| Confusional statePsychiatric disorders | 2/49 | 0/32 | 0/26 | 0/4 | 2/111 |
| HaematemesisGastrointestinal disorders | 2/49 | 0/32 | 0/26 | 0/4 | 2/111 |
| SepsisInfections and infestations | 2/49 | 0/32 | 0/26 | 0/4 | 2/111 |
| Event | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other | Total |
|---|---|---|---|---|---|
| HyperphosphataemiaMetabolism and nutrition disorders | 45/49 | 27/32 | 17/26 | 4/4 | 93/111 |
| StomatitisGastrointestinal disorders | 27/49 | 17/32 | 13/26 | 2/4 | 59/111 |
| AlopeciaSkin and subcutaneous tissue disorders | 20/49 | 17/32 | 8/26 | 0/4 | 45/111 |
| DiarrhoeaGastrointestinal disorders | 19/49 | 17/32 | 7/26 | 0/4 | 43/111 |
| NauseaGastrointestinal disorders | 11/49 | 8/32 | 6/26 | 2/4 | 27/111 |
| PyrexiaGeneral disorders | 2/49 | 3/32 | 1/26 | 2/4 | 8/111 |
| DysgeusiaNervous system disorders | 10/49 | 14/32 | 6/26 | 0/4 | 30/111 |
| ConstipationGastrointestinal disorders | 18/49 | 13/32 | 6/26 | 0/4 | 37/111 |
| Decreased appetiteMetabolism and nutrition disorders | 10/49 | 12/32 | 5/26 | 0/4 | 27/111 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/49 | 11/32 | 1/26 | 0/4 | 23/111 |
| Age, Continuous(years) | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other | Total |
|---|---|---|---|---|---|
| Mean | 59.4 ± 11.51 | 66.0 ± 10.04 | 61.5 ± 13.32 | 48.0 ± 14.45 | 61.4 ± 12.11 |
| Sex: Female, Male(Participants) | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other | Total |
|---|---|---|---|---|---|
| Female | 28 | 19 | 14 | 1 | 62 |
| Male | 21 | 13 | 12 | 3 | 49 |
| Race/Ethnicity, Customized(Participants) | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other | Total |
|---|---|---|---|---|---|
| White | 38 | 20 | 16 | 0 | 74 |
| Black or African American | 0 | 0 | 1 | 0 | 1 |
| Asian | 9 | 9 | 7 | 4 | 29 |
| Participant Declined to Provide | 1 | 0 | 0 | 0 | 1 |
| Not Available | 0 | 1 | 0 | 0 | 1 |
| Not Required in Country of Origin | 0 | 1 | 0 | 0 | 1 |
| Missing | 1 | 1 | 2 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements | Cohort B: Known or Likely Activating FGFR1-3 Mutations | Cohort C: Other FGFR Mutations or Arrangements | Other | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 1 | 0 | 3 |
| Not Hispanic or Latino | 44 | 25 | 20 | 3 | 92 |
| Not Reported | 2 | 2 | 3 | 1 | 8 |
| Unknown | 1 | 2 | 0 | 0 | 3 |
| Captured as "Other" | 0 | 1 | 0 | 0 | 1 |
| Missing | 1 | 1 | 2 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Oct 2019 to primary completion in Mar 2022, 29 months.
Results were first posted in Mar 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemigatinib